Doctor profile · Federal record
Dr. Bhavesh Balar, MD
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Freehold, NJ
- NPI 1134113376
- Accepts Medicare
- MIPS 86.8 / 100 · 2023
- 28 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
326 Professional View Dr
Freehold, NJ 077287904
(732) 431-8400
fax (732) 431-0114
Credentials & registration
- NPI registered
- September 2005 — 21 yrs on file
- Profile last updated
- February 24, 2016
- Year of graduation
- 1998 — 28 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- New Jersey #25MA07783700
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1134113376. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
229,726
Distinct HCPCS
10
Medicare allowed
$5,247,140
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J9299 |
Injection, nivolumab, 1 mg | 36,240 | 12 | $30 | |
J9271 |
Injection, pembrolizumab, 1 mg | 32,200 | 35 | $54 | |
J1627 |
Injection, granisetron, extended-release, 0.1 mg | 19,300 | 36 | $6 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 17,772 | 14 | $0 | |
J0897 |
Injection, denosumab, 1 mg | 16,500 | 126 | $23 | |
J0185 |
Injection, aprepitant, 1 mg | 15,340 | 30 | $2 | |
J1437 |
Injection, ferric derisomaltose, 10 mg | 13,800 | 97 | $21 | |
J1756 |
Injection, iron sucrose, 1 mg | 8,601 | 28 | $0 | |
J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units | 8,361 | 55 | $7 | |
Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 7,880 | 37 | $8 |
In context: peer comparison
Among 2 peers in Freehold Hematology & Oncology Physician, average services per provider: 3,261. This provider delivers 70× the peer median.Open Payments
Industry payments received
All-time total
$3,105
Transactions
95
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $1,119.83 | |
| Daiichi Sankyo INC. | 12 | $259.39 | |
| Pfizer INC. | 12 | $140.69 | |
| Stryker Corporation | 1 | $115.26 | |
| Eisai INC. | 6 | $110.02 | |
| Abbvie INC. | 7 | $106.48 | |
| Janssen Biotech, INC. | 6 | $104.89 | |
| Gilead Sciences, INC. | 5 | $81.62 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $80.16 | |
| Celgene Corporation | 5 | $78.54 | |
| BeiGene USA, INC. | 4 | $65.30 | |
| Incyte Corporation | 4 | $64.81 | |
| Astellas Pharma US INC | 3 | $61.35 | |
| Pharmacosmos Therapeutics INC. | 3 | $57.74 | |
| Merck Sharp & Dohme LLC | 3 | $56.80 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
538
Patients
111
Total drug cost
$2,300,601
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 169 | 67 | $6,867 |
| Eliquis (Apixaban) | Brand | 104 | 30 | $99,500 |
| Erleada (Apalutamide) | Brand | 32 | 0 | $468,813 |
| Xarelto (Rivaroxaban) | Brand | 29 | 0 | $22,389 |
| Prednisone | Generic | 25 | 0 | $173 |
| Acyclovir | Generic | 21 | 0 | $687 |
| Cabometyx (Cabozantinib S-Malate) | Brand | 21 | 0 | $541,869 |
| Imbruvica (Ibrutinib) | Brand | 21 | 0 | $335,549 |
| Jakafi (Ruxolitinib Phosphate) | Brand | 20 | 0 | $338,414 |
| Dexamethasone | Generic | 19 | 14 | $556 |
Hospital affiliations
Frequently asked questions
What is Dr. Bhavesh Balar's medical specialty?
Dr. Bhavesh Balar practices Hematology & Oncology Physician in Freehold, NJ.
Where does Dr. Bhavesh Balar practice?
Dr. Bhavesh Balar practices at 326 Professional View Dr, Freehold, NJ 077287904. Office phone: 7324318400.
What is Dr. Bhavesh Balar's NPI?
Dr. Bhavesh Balar's National Provider Identifier (NPI) is 1134113376, issued by NPPES.
Does Dr. Bhavesh Balar accept Medicare assignment?
Yes. Dr. Bhavesh Balar accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Bhavesh Balar commonly perform?
Top Medicare-reported procedures in 2023: Injection, nivolumab, 1 mg (HCPCS J9299); Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, granisetron, extended-release, 0.1 mg (HCPCS J1627). Source: CMS Medicare Physician & Other Practitioners file.